Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-05-05
1998-04-21
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514772, A61K 31415
Patent
active
057418055
ABSTRACT:
There is disclosed a method for treating a patient suffering from xerostomia, xerophthalmia or excessive intraocular pressure. The method comprises administering to said patient a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof, in an amount sufficient to maintain a blood serum level of pilocarpine in said patient of from about 5 to about 40 ng/ml, for a period of at least 6 hours. Controlled release unit dosage forms containing pilocarpine are also disclosed.
REFERENCES:
patent: 3640741 (1972-02-01), Etes
patent: 4151270 (1979-04-01), Ream et al.
patent: 4209505 (1980-06-01), Mikhail
patent: 4438100 (1984-03-01), Balslev et al.
patent: 4615697 (1986-10-01), Robinson
patent: 4820506 (1989-04-01), Kleinberg et al.
patent: 4900552 (1990-02-01), Sanvordeker et al.
patent: 4906455 (1990-03-01), Hoerman
patent: 4917674 (1990-04-01), Molinoff
patent: 4938963 (1990-07-01), Parnell
patent: 4988679 (1991-01-01), Chavkin et al.
Fox et al., "Xerostomia: evaluation of a symptom with increasing significance" J. Am. Dent. Assoc. (1985) 110:519-525.
Chencharick et al., "Nutritional consequences of the radiotherapy of head and neck cancer" Cancer (1983) 51:811-815.
Fox, "Management of salivary gland hypofunction and dry mouth (xerostomia)" Head and Neck Cancer, Fee et al., eds., (1990) pp. 322-324.
Fox, "Systemic therapy of salivary gland hypofunction" J. Dent. Res. (1987)66:689-692.
LeVeque et al., "A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients" J. Clin. Oncol. (1993) 11:1124-1131.
Johnson et al., "Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer" N. Engl. J. Med. (1993) 329:390-395.
Greenspan et al., "Effectiveness of pilocarpine in postradiation xerostomia" Cancer (1987) 59:1123-1125.
Dawes, "The composition of human saliva secreted in response to a gustatory stimulus and to pilocarpine" J. Physiol. (London) (1966) 183:360-368.
Mandel et al., "The effect of pharmacologic agents on salivary secretion and composition. II. Isoproterenol, alpha and beta adrenergic blockers" J. Oral. Ther. Pharmacol. (1968) 4:260-269.
Fox et al., "Pilocarpine for the treatment of xerostomia associated with salivary gland dysfunction" Oral Surg. Oral Med. Oral Pathol. (1986) 61:243-248.
Rhodus et al., "Effects of pilocarpine on salivary flow in patients with Sjogren's syndrome" Oral Surg. Oral Med. Oral Pathol. (1991) 72: 545-549.
Greco et al., "Systemic pilocarpine toxicity in the treatment of angle closure glaucoma" Ann. Opthalmol. (1973) 5:57-59.
Kastl, "Inadvertent systemic injection of pilocarpine. Case report" Arch. Opthalmol. (1987) 105:28-29.
Littmann et al., "Severe symptomatic atrioventricular block induced by pilocarpine eye drops" Arch. Intern. Med. (1987) 147:586-587.
Weaver et al., "Pilocarpine disposition and salivary flow responses following intravenous administration to dogs" Pharm. Res. (1992) 9:1064-1069.
Valdez et al., "Interactions of the salivary and gastrointestinal systems. II. Effects of salivary gland dysfunction on the gastrointestinal tract" Dig. Dis. (1991) 9:210-218.
Hughes et al., "Oral-pharyngeal dysphagia: A common sequela of salivary gland dysfunction" Dysphagia (1987) 1:173-177.
Caruso et al., "Objective measures of swallowing in patients with primary Sjogren's syndrome" Dysphagia (1989) 4:101-105.
Helm, "Role of saliva in esophageal function and disase" Dysphagia (1989) 4:76-84.
Korsten et al., "Chronic xerostomia increases esophageal acid exposure and is associated with esophageal injury" Am. J. Med. (1991) 90:701-706.
Schuller et al., "Treatment of radiation side effects with oral pilocarpine" J. Surg. Oncol. (1989) 42:272-276.
Severin, "Keratoconjunctivitis sicca" Vet. Clin. North Am. (1973) 3:407-422.
Pavan-Langston, "Potential use of ocular-insert therapy in dry eyes" Int. Opthalmol. Clin. (1973) 13:231-238.
Deshpande et al., "Sustained release ophthalmic formulations of pilocarpine" J. Pharm. Pharmacol. (1988) 41:197-200.
Lehr et al., "A surface energy analysis of mucoadhesion: Contact angle measurements on polycarbophil and pig intestinal mucosa in physiologically relevant fluids" Pharm. Res. (1992) 9:70-75.
Physician's Desk Reference for Ophthalmology, Walsh, J.B. et al., eds., 16th Edition (1988) pp. 3, 11.
Abstract of Mamtani et al., "Comparison of total costs of administering calcium polycarbophil and psyllium mucilloid in an institutional setting" Clin. Therap. (1990) 12:22-25.
Embase Abstract of Arch. Intern. Med. (USA), 1991, 151/6 (1149-1152). Fox et al.
Fay Zohreh
Oramed, Inc.
LandOfFree
Controlled release pilocarpine delivery system does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Controlled release pilocarpine delivery system, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlled release pilocarpine delivery system will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2057780